<DOC>
	<DOCNO>NCT01155791</DOCNO>
	<brief_summary>Selenium , form inorganic Sodium Selenite , may useful treat exist prostate cancer . This idea base data laboratory show 1 ) prostate cancer cell sensitive Selenium ( Sodium Selenite ) -induced apoptosis normal prostate epithelial cell , 2 ) Selenite induces significant growth inhibition well establish prostate cancer tumor mice dos detectable toxicity , 3 ) Selenite disrupt AR signaling , inhibition AR expression activity Selenite occur via redox mechanism involve GSH , superoxide , Sp1 . Altogether , finding suggest Selenium may useful variety potential indication natural history prostate cancer , include hormone sensitive castrate resistant prostate cancer , single agent , combination radiation , chemotherapy conventional hormone therapy . Selenite potential novel inhibitor AR expression function prostate cancer .</brief_summary>
	<brief_title>Phase I Sodium Selenite Combination With Docetaxel Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Selenious Acid</mesh_term>
	<mesh_term>Sodium Selenite</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate 2 . Castrationresistant prostate cancer require follow 3 criterion : Failure first line bilateral orchiectomy therapy LHRH agonist , A rise PSA 3 consecutive occasion least 1 week apart ( limited 30 day screen period ) , AND A castrate level testosterone ( &lt; 50ng/dL ) 3 . PSA double time ( PSADT ) &gt; 1 month 4 . Failure docetaxel chemotherapy define rise PSA . 5 . A minimum PSA 2 ng/mL 6 . Age &gt; =18 year 7 . Life expectancy great 6 month 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Karnofsky performance status &gt; =80 % 9 . Bone metastases allow 10 . The subject QTcB ( Bazett correct ) QTcF ( Frederica correct ) &lt; 470 msec . 11 . Ability understand willingness sign write informed consent document . 12 . Willingness stay docetaxel chemotherapy despite rise PSA level . 1 . Radiotherapy prostate cancer within 28 day prior Day 1 . 2 . More 1 prior chemotherapy 3 . Inadequate organ function , evidence follow screening : Absolute neutrophil count ( ANC ) &lt; 1500/uL Platelet count &lt; = 100 x 10^9/L Total bilirubin &gt; = ULN AST , and/or ALT &gt; 1.5 x upper limit normal ( ULN ) concomitant alkaline phosphastase &gt; 2.5 X ULN Serum creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 9 g/dL 4 . Men reproductive potential agree use accept effective method contraception study treatment period least 3 month completion study treatment . 5 . History malignancy within 5 year prior Day 1 except tumor negligible risk metastasis death , adequately control basal cell carcinoma , squamouscell carcinoma skin , earlystage bladder cancer 6 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . 7 . Known prior treat brain metastasis . 8 . History hypersensitivity docetaxel 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant vascular disease ( e.g . aortic aneurysm , aortic dissection ) , symptomatic peripheral vascular disease , psychiatric illness/social situation would limit compliance study requirement . 10 . History myocardial infarction unstable angina within 6 month prior study enrollment 11 . History stroke transient ischemic attack within 6 month prior study enrollment 12 . The subject know positive human immunodeficiency virus ( HIV ) receive antiretroviral 12 . Willingness stay docetaxel chemotherapy despite rise PSA level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>